Experimental immunotherapy combo for tough colorectal cancer trial pulled before start

NCT ID NCT06557278

Terminated Disease control Sponsor: Mirror Biologics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test an experimental immunotherapy called AlloStim combined with a checkpoint inhibitor (avelumab) in people with advanced colorectal cancer that had stopped responding to multiple prior treatments. The trial was withdrawn before any participants were enrolled, so no data on safety or effectiveness were collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AlloStim (experimental immunotherapy) plus avelumab (anti-PDL1 checkpoint inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced colorectal cancer that hasn't responded to other therapies.
What could go wrong: This trial was withdrawn before enrolling any participants, so no results are available. The combination is experimental and early-stage, with unknown safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Hirschfield Oncology Center

Brooklyn, New York, 11206, United States
Mt. Sinai Comprehensive Cancer Center

Miami Beach, Florida, 33140, United States
New York Cancer and Blood Specialists

Shirley, New York, 11967, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.